Drug Type Microbiota |
Synonyms CJRB-101 |
Target |
Action agonists |
Mechanism TLR4 agonists(Toll like receptor 4 agonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Advanced cancer | Phase 2 | United States | 11 Sep 2023 | |
| Advanced cancer | Phase 2 | South Korea | 11 Sep 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | United States | 11 Sep 2023 | |
| Advanced Malignant Solid Neoplasm | Phase 2 | South Korea | 11 Sep 2023 | |
| Melanoma | Phase 2 | United States | 11 Sep 2023 | |
| Melanoma | Phase 2 | South Korea | 11 Sep 2023 | |
| Neoplasm Metastasis | Phase 2 | United States | 11 Sep 2023 | |
| Neoplasm Metastasis | Phase 2 | South Korea | 11 Sep 2023 | |
| Non-Small Cell Lung Cancer | Phase 2 | United States | 11 Sep 2023 | |
| Non-Small Cell Lung Cancer | Phase 2 | South Korea | 11 Sep 2023 |
Phase 1/2 | 32 | srgzwegdld(otwtwurblz) = Only 1 patient (3.2%) experienced grade≥3 TRAE which was anemia related to CJRB-101 weejhzeqad (cocpspctkm ) | Positive | 30 May 2025 | |||





